Thomas J. Guzzo MD, MPHChief of Urology and Associate Program Director, University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Dr. Guzzo is Chief of Urology and Associate Program Director at the University of Pennsylvania. He is a graduate of Temple University School of Medicine. He completed his general surgery internship and urology residency at the Hospital of the University of Pennsylvania. Dr. Guzzo completed a fellowship at the James Buchanan Brady Urological Institute of the Johns Hopkins Hospital in urologic oncology. During his fellowship he also earned a Masters in Public Health from the Johns Hopkins Bloomberg School of Public Health. He is extensively trained in the treatment of all aspects of urologic malignancies including open, laparoscopic, endoscopic and robotic surgical treatment for such malignancies.
Dr. Guzzo’s clinical areas of expertise include the surgical treatment of prostate, bladder, kidney and testicular cancer. He has one of the largest urologic oncology practices in the region and specializes in open, endoscopic and minimally invasive surgical procedures. Additionally, He is a member of the Penn Academy of master clinicians.
Dr. Guzzo also maintains a productive urologic oncology research program. He is a Prostate Cancer Foundation young investigator award recipient. He is the director of the urologic oncology research laboratory at the University of Pennsylvania. He has published over 120 peer-reviewed manuscripts, over a dozen book chapters and is the editor of two text books in urology.
DisclosuresNo disclosures to report.
Recent Contributions to PracticeUpdate:
- Impact of (18) F-Fluorodeoxyglucose (FDG)-Positron-Emission Tomography/Computed Tomography (PET/CT) on Management of Patients With Carcinoma Invading Bladder Muscle
- Immediate Post-Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non-Muscle-Invasive Bladder Cancer Recurrences: An Updated Meta-Analysis on 2548 Patients and Quality-of-Evidence Review
- The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients With Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial
- Lymphadenectomy for Bladder Cancer at the Time of Radical Cystectomy
- Bladder Preservation in the Treatment of Muscle-Invasive Bladder Cancer (MIBC): A Review of the Literature and a Practical Approach to Therapy
- The Latest on Prostate Cancer Screening